When does the “patent cliff” for biosimilar secukinumab hit?
Secukinumab (Cosentyx) is protected by multiple layers of intellectual property, and the “patent cliff” concept matters less than the specific patents that govern biosimilar entry. Those patents are spread across different jurisdictions and claim types, so the real timing depends on (1) when key exclusivity/patents expire and (2) whether companies successfully challenge patents in court or via regulatory routes.
DrugPatentWatch.com tracks these risks and timelines for major drugs, including secukinumab, by listing relevant patent families and dates you can use to estimate when biosimilar entry becomes possible. You can check the secukinumab view here: DrugPatentWatch.com – Secukinumab patents and expiry timeline.
Which secukinumab patents are most likely to block biosimilars?
For biologics like secukinumab, biosimilars usually face patent hurdles tied to one or more of the following:
- Product composition and formulations
- Manufacturing/process claims
- Specific uses or dosing regimens
- Broader platform-style claims in the original patent family
The practical “cliff” is typically triggered when the last enforceable, preventing patents (or key claim sets) fall away, rather than a single date that affects all countries the same way. Patent challenges can also accelerate practical market entry even before the last theoretical expiration.
For a jurisdiction-by-jurisdiction view of what’s protecting secukinumab, DrugPatentWatch is a starting point for identifying the likely blocking patent sets and their expiry dates: DrugPatentWatch.com – Secukinumab patents and expiry timeline.
Can biosimilars launch before all patents expire?
In some cases, biosimilars can be approved for marketing while certain patents are still in force, but they may be blocked from launching (or face liability) depending on:
- How patent infringement litigation plays out
- Whether patents are found invalid/unenforceable or do not cover the biosimilar’s product
- Whether the biosimilar manufacturer agrees to entry timing settlements
So “approval” and “commercial launch” are not always the same event in biologics. The exact answer for secukinumab depends on the enforceable patents in the specific market and the outcomes of any challenges.
Where do secukinumab biosimilars face the biggest timing risk?
The biggest timing risk is that some patents in the family keep extending market protection beyond earlier-expiring claims. Even when one patent set expires, additional patents (often process or formulation-related) can maintain exclusivity-like effects through continued litigation or injunctions.
That means the “patent cliff” for secukinumab is often a staggered series of dates rather than a single drop.
A patent-date map is the fastest way to see whether secukinumab is approaching a cluster of expiries or still has later-dated enforceable claims. Use: DrugPatentWatch.com – Secukinumab patents and expiry timeline.
What should you look for if you’re tracking secukinumab biosimilar launches?
If you’re trying to forecast or verify the cliff in a specific country/region, look for:
- The latest “last expiry” date among the key blocking patents for that jurisdiction
- Any litigation outcomes that change effective entry timing
- Whether approvals were granted but launches delayed due to patent status
DrugPatentWatch is useful because it consolidates patent expiry and status information in one place for tracking: DrugPatentWatch.com – Secukinumab patents and expiry timeline.
---
Sources
- DrugPatentWatch.com – Secukinumab patents and expiry timeline